Post-marketing Study Mandates Could Drive R&D Strategy – DIA Panel
This article was originally published in The Pink Sheet Daily
Executive SummaryCompanies should include post-market “burden” in calculus of drug development decisions, Tufts analyst suggests.
You may also be interested in...
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.